|1.||Shen, Ji-Long: 2 articles (10/2013 - 08/2013)|
|2.||Chen, He: 2 articles (10/2013 - 08/2013)|
|3.||Huo, Xing-Xing: 2 articles (10/2013 - 08/2013)|
|4.||Pisanelli, Stefania: 1 article (07/2015)|
|5.||Li, Erzhen: 1 article (07/2015)|
|6.||Lv, Lingyun: 1 article (07/2015)|
|7.||Wang, Liwen: 1 article (07/2015)|
|8.||Bedogni, Giorgio: 1 article (07/2015)|
|9.||Zheng, Ping: 1 article (07/2015)|
|10.||Zuccotti, Gian Vincenzo: 1 article (07/2015)|
12/01/1994 - "The results indicate that pidotimod is significantly more effective than placebo against infectious relapses in patients suffering from chronic bronchitis. "
12/01/1994 - "The efficacy of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in the management of infectious exacerbations of chronic bronchitis was evaluated in a double-blind, placebo-controlled study in parallel groups over 5 months (60 days of treatment and 90 days of follow-up). "
12/01/1994 - "Primary objective of the investigation was to verify the efficacy of pidotimod against infectious exacerbations in patients affected with chronic bronchitis. "
12/01/1994 - "Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis."
12/01/1994 - "A multicentre double-blind placebo-controlled study was conducted in order to assess the effects of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6), a new synthetic biological response modifier, on the clinical picture of bacterial exacerbations of chronic bronchitis. "
04/01/1999 - "The beneficial effects of pidotimod were also confirmed by a series of recordings made over the 90-day treatment period which showed a significant reduction in the number of days of fever, severity of the signs and symptoms of the acute episodes and use of antibiotics and antipyretic drugs. "
12/01/1994 - "The protective effect produced by pidotimod was also confirmed by a series of recordings made over the five-month observation period, which showed a significant reduction in the number of days of fever, the severity of the signs and symptoms of acute episodes, use of antibiotics and antipyretic drugs and absence from school or nursery school. "
06/01/2015 - "[Effectiveness of pidotimod in combination with bacterial lysates in the treatment of the pfapa (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) syndrome]."
04/01/2009 - "These activities have been applied in clinical studies demonstrating the efficacy of pidotimod in reducing the rate of recurrent infections of the upper respiratory and urinary tracts in children. "
01/01/2013 - "A study was therefore designed to evaluate in vitro whether pidotimod, a synthetic dipeptide able to stimulate the inflammatory and immune effector cells, could activate bronchial epithelial cell functions involved in response to infections. "
04/01/1999 - "In this study we have evaluated the effects of the new synthetic immunomodulator pidotimod in recurrent infections of the upper respiratory tract in a group of children with DS. "
12/01/1994 - "Since other studies demonstrated that pidotimod displays an immunopotentiating activity also on macrophages and granulocytes, the drug is useful to increase the immune defense during infections. "
03/01/2002 - "Patients of both sexes, 2 to 16 years old, that had at least four episodes of acute respiratory infection, during the previous six months, administering a dose of 400 mg of pidotimod later, twice a day. "
08/01/2013 - "This is the first report of the preventive effect of pidotimod on reactivated toxoplasmosis."
08/01/2013 - "Preventive effect of pidotimod on reactivated toxoplasmosis in mice."
08/01/2013 - "To investigate the efficacy of pidotimod as a preventive treatment, we used a murine model of reactivated toxoplasmosis with cyclophosphamide (CY)-induced immunosuppression. "
10/01/2013 - "To study the inhibition effect of pidotimod (PT) on dexamethasone (Dem)-induced reactivated toxoplasmosis in mice. "
10/01/2013 - "Pidotimod can inhibit activation of latent Toxoplasma gondii infection induced by dexamethasone in mice. "
12/01/1994 - "The therapeutic efficacy of the synthetic immunostimulant pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was evaluated in a double-blind placebo-controlled study in parallel groups in the management of recurrences in 235 children with recurrent tonsillitis. "
12/01/1994 - "Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood."
01/01/1992 - "Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood."
|1.||Anti-Bacterial Agents (Antibiotics)
|8.||Ascorbic Acid (Vitamin C)
|1.||Laser Therapy (Surgery, Laser)